Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration

被引:93
|
作者
Rohm, Markus [1 ,2 ]
Tresp, Volker [2 ]
Mueller, Michael [1 ]
Kern, Christoph [1 ]
Manakov, Ilja [1 ,2 ]
Weiss, Maximilian [1 ]
Sim, Dawn A. [3 ]
Priglinger, Siegfried [1 ]
Keane, Pearse A. [3 ]
Kortuem, Karsten [1 ,3 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Comp Sci, Munich, Germany
[3] Moorfields Eye Hosp, London, England
关键词
INTRAVITREAL AFLIBERCEPT; DIABETIC-RETINOPATHY; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; EDEMA; PROGRESSION; TRIAL; EYE;
D O I
10.1016/j.ophtha.2017.12.034
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To predict, by using machine learning, visual acuity (VA) at 3 and 12 months in patients with neovascular age-related macular degeneration (AMD) after initial upload of 3 anti-vascular endothelial growth factor (VEGF) injections. Design: Database study. Participants: For the 3-month VA forecast, 653 patients (379 female) with 738 eyes and an average age of 74.1 years were included. The baseline VA before the first injection was 0.54 logarithm of the minimum angle of resolution (logMAR) (+/- 0.39). A total of 456 of these patients (270 female, 508 eyes, average age: 74.2 years) had sufficient follow-up data to be included for a 12-month VA prediction. The baseline VA before the first injection was 0.56 logMAR (+/- 0.42). Methods: Five different machine-learning algorithms (AdaBoost.R2, Gradient Boosting, Random Forests, Extremely Randomized Trees, and Lasso) were used to predict VA in patients with neovascular AMD after treatment with 3 anti-VEGF injections. Clinical data features came from a data warehouse (DW) containing electronic medical records (41 features, e.g., VA) and measurement features from OCT (124 features, e.g., central retinal thickness). The VA of patient eyes excluded from machine learning was predicted and compared with the ground truth, namely, the actual VA of these patients as recorded in the DW. Main Outcome Measures: Difference in logMAR VA after 3 and 12 months upload phase between prediction and ground truth as defined. Results: For the 3-month VA forecast, the difference between the prediction and ground truth was between 0.11 logMAR (5.5 letters) mean absolute error (MAE)/0.14 logMAR (7 letters) root mean square error (RMSE) and 0.18 logMAR (9 letters) MAE/0.2 logMAR (10 letters) RMSE. For the 12-month VA forecast, the difference between the prediction and ground truth was between 0.16 logMAR (8 letters) MAE/0.2 logMAR (10 letters) RMSE and 0.22 logMAR (11 letters) MAE/0.26 logMAR (13 letters) RMSE. The best performing algorithm was the Lasso protocol. Conclusions: Machine learning allowed VA to be predicted for 3 months with a comparable result to VA measurement reliability. For a forecast after 12 months of therapy, VA prediction may help to encourage patients adhering to intravitreal therapy. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 50 条
  • [1] Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration
    Abdallah Abbas
    Ciara O’Byrne
    Dun Jack Fu
    Gabriella Moraes
    Konstantinos Balaskas
    Robbert Struyven
    Sara Beqiri
    Siegfried K. Wagner
    Edward Korot
    Pearse A. Keane
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2461 - 2473
  • [2] Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration
    Abbas, Abdallah
    O'Byrne, Ciara
    Fu, Dun Jack
    Moraes, Gabriella
    Balaskas, Konstantinos
    Struyven, Robbert
    Beqiri, Sara
    Wagner, Siegfried K.
    Korot, Edward
    Keane, Pearse A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2461 - 2473
  • [3] Machine Learning to Predict Visual Acuity Outcomes from Imaging Biomarkers in Neovascular Age-Related Macular Degeneration
    Waldstein, Sebastian
    Bogunovic, Hrvoje
    Sadeghipour, Amir
    Schlegl, Thomas
    Gerendas, Bianca S.
    Osborne, Aaron
    Schmidt-Erfurth, Ursula
    OPHTHALMOLOGICA, 2016, 236 : 3 - 3
  • [4] Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration (nAMD) using machine learning
    Kikuchi, Yusuke
    Neubert, Ales
    Dai, Jian
    Ruiz, Carlos Quezada
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [5] Visual acuity and its decrease in classic neovascular age-related macular degeneration
    Behrendt, CE
    OPHTHALMIC EPIDEMIOLOGY, 2004, 11 (05) : 359 - 367
  • [6] Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration
    Sawada, Tomoko
    Yasukawa, Tsutomu
    Imaizumi, Hiroko
    Matsubara, Hisashi
    Kimura, Kazuhiro
    Terasaki, Hiroto
    Ishikawa, Hiroto
    Murakami, Tomoya
    Takeuchi, Masaru
    Mitamura, Yoshinori
    Mizusawa, Yutaro
    Takamura, Yoshihiro
    Murata, Toshinori
    Kogo, Jiro
    Ohji, Masahito
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2023, 67 (02) : 149 - 155
  • [7] Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration
    Tomoko Sawada
    Tsutomu Yasukawa
    Hiroko Imaizumi
    Hisashi Matsubara
    Kazuhiro Kimura
    Hiroto Terasaki
    Hiroto Ishikawa
    Tomoya Murakami
    Masaru Takeuchi
    Yoshinori Mitamura
    Yutaro Mizusawa
    Yoshihiro Takamura
    Toshinori Murata
    Jiro Kogo
    Masahito Ohji
    Japanese Journal of Ophthalmology, 2023, 67 : 149 - 155
  • [8] Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning
    Fu, Dun Jack
    Faes, Livia
    Wagner, Siegfried K.
    Moraes, Gabriella
    Chopra, Reena
    Patel, Praveen J.
    Balaskas, Konstantinos
    Keenan, Tiarnan D. L.
    Bachmann, Lucas M.
    Keane, Pearse A.
    OPHTHALMOLOGY RETINA, 2021, 5 (11): : 1074 - 1084
  • [9] Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity
    Kato, Aki
    Yasukawa, Tsutomu
    Suga, Keiji
    Hirano, Yoshio
    Nozaki, Miho
    Yoshida, Munenori
    Ogura, Yuichiro
    OPHTHALMOLOGICA, 2015, 233 (01) : 27 - 34
  • [10] Intravitreal Bevacizumab Injection in Patients With Neovascular Age-Related Macular Degeneration and Low Visual Acuity
    El Matri, L.
    Bouraoui, R.
    Landolsi, H.
    Kort, F.
    Chebil, A.
    Limaiem, R.
    Mghaieth, F.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)